Joint meeting with Fatty Liver Disease and Multi-System Complications
Hepatobiliary Cancers: Pathobiology and Translational Advances
March 22-24, 2021 | 10:00AM EDT | 2:00PM UTC | 3:00PM CET*
*Program is in development and subject to change
Joint Meetings
Your registration provides you with access to both the “Fatty Liver Disease and Multi-System Complications” and “Hepatobiliary Cancers: Pathobiology and Translational Advances” eSymposia events. Use the link below to explore the joint meeting features, including live plenary sessions, On Demand talks, posters, forums, job postings, 1:1 Connect appointments and more. This joint meeting access is designed to facilitate cross-disciplinary insights and collaborations to drive both fields in exciting new directions!
Preferred
(EDT)
Happening
Any Time
Content
Dates
Tracks
Speakers
Rooms
Showing results 1 - 8 of 8
Monday, March 22, 2021
[Joint Session] Welcoming Remarks and Keynote Session
10:00 AM - 11:10 AM EDT
Monday, March 22, 2021Room: Multi Tech Session Co-Chairs
Jay Horton, MD
University of Texas Southwestern Medical Center
Alphonse Sirica, PhD
Virginia Commonwealth University
[Joint Session] Welcoming Remarks and Keynote Session
[NOT AVAILABLE ON DEMAND] PNPLA3's Role in NAFLD
10:00 AM - 10:35 AM EDT
Monday, March 22, 2021Room: V100 Atticus Kiser Speaker
Helen Hobbs, MD
University of Texas Southwestern Medical Center
[Joint Session] Welcoming Remarks and Keynote Session
Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers
10:35 AM - 11:10 AM EDT
Monday, March 22, 2021Room: V100 Atticus Kiser Speaker
Hashem El-Serag, MD
Baylor College of Medicine
[Joint Session] Welcoming Remarks and Keynote Session
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
11:10 AM - 1:00 PM EDT
Monday, March 22, 2021Room: Multi Tech Session Co-Chairs
Jay Horton, MD
University of Texas Southwestern Medical Center
Alphonse Sirica, PhD
Virginia Commonwealth University
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
A TGF-ß-ALDH2 Axis in Obesity, Metabolic Syndrome, and HCC
11:10 AM - 11:35 AM EDT
Monday, March 22, 2021Room: V300 Guy Coombes Speaker
Lopa Mishra, MD
George Washington University
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
Coffee Break
11:35 AM - 11:55 AM EDT
Monday, March 22, 2021[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
The Gut-Liver Axis in Liver Cancer Risk Conditions
11:55 AM - 12:20 PM EDT
Monday, March 22, 2021Room: V200 Ronney Laws Speaker
Maria Rescigno, PhD
Humanitas University
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
Lipid Dysregulation in Inflammation, NASH, and Cancer
12:20 PM - 12:45 PM EDT
Monday, March 22, 2021Room: V200 Ronney Laws Speaker
Daniel Heller, PhD
Memorial Sloan Kettering Cancer Center
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
Short Talk: The α1-Na/K-ATPase/Src-p/PI3K Pathway Modulates the Survivin-SMAC Apoptotic “Switch” in NASH Related Hepatocellular Carcinoma: A Translational Study
12:45 PM - 1:00 PM EDT
Monday, March 22, 2021Room: V200 Ronney Laws Speaker
Juan Sanabria, MD
Marshall University/Case Western Reserve University
[Joint Session] Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers
[Joint Session] Career Roundtable
2:30 PM - 3:30 PM EDT
Monday, March 22, 2021Panelists
Kendra Bence, PhD
Pfizer Inc.
Augusto Villanueva Rodriguez, MD, PhD
Icahn School of Medicine at Mount Sinai
Xin Wei Wang, PhD
NCI, National Institutes of Health
Career Roundtable
Tumor Microenvironment and Hepatobiliary Cancers
5:00 PM - 8:10 PM EDT
Monday, March 22, 2021Room: Multi Tech Session Co-Chairs
Lopa Mishra, MD
George Washington University
Gregory Gores, MD
Mayo Clinic
Tumor Microenvironment and Hepatobiliary Cancers
Role of Cancer Associated Fibroblasts in Cholangiocarcinoma
5:00 PM - 5:30 PM EDT
Monday, March 22, 2021Room: V400 Ryan Reid Speaker
Silvia Affo, PhD
Columbia University
Tumor Microenvironment and Hepatobiliary Cancers
Mechanisms of Immune Escape in Hepatocellular Carcinoma
5:30 PM - 6:00 PM EDT
Monday, March 22, 2021Room: V400 Ryan Reid Speaker
Amaia Lujambio, PhD
Icahn School of Medicine at Mount Sinai
Tumor Microenvironment and Hepatobiliary Cancers
The Desmoplastic Reaction and Intrahepatic Cholangiocarcinoma Progression: CAFs, Select Molecular Drivers, and Prognostic Implications
6:00 PM - 6:30 PM EDT
Monday, March 22, 2021Room: V400 Ryan Reid Speaker
Alphonse Sirica, PhD
Virginia Commonwealth University
Tumor Microenvironment and Hepatobiliary Cancers
Coffee Break
6:30 PM - 6:40 PM EDT
Monday, March 22, 2021Tumor Microenvironment and Hepatobiliary Cancers
Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
6:40 PM - 7:10 PM EDT
Monday, March 22, 2021Speaker
Gregory Gores, MD
Mayo Clinic
Tumor Microenvironment and Hepatobiliary Cancers
Speaker
Wen-Xing Ding, PhD
University of Kansas Medical Center
Tumor Microenvironment and Hepatobiliary Cancers
Short Talk: Requirement of Hippo Signaling Cascade during AXIN1 Mutation Driven Hepatocarcinogenesis
7:40 PM - 7:55 PM EDT
Monday, March 22, 2021Speaker
Haichuan Wang
University of California, San Francisco
Tumor Microenvironment and Hepatobiliary Cancers
Short Talk: Long Non-Coding RNA NIHCOLE Promotes the DNA Damage Repair of Hepatocellular Carcinoma Cells
7:55 PM - 8:10 PM EDT
Monday, March 22, 2021Speaker
Juan Pablo Unfried, PhD
University of Navarra
Tumor Microenvironment and Hepatobiliary Cancers
Tuesday, March 23, 2021
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
10:00 AM - 1:10 PM EDT
Tuesday, March 23, 2021Room: Multi Tech Session Co-Chairs
Gregory Gores, MD
Mayo Clinic
Alphonse Sirica, PhD
Virginia Commonwealth University
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Liver Cancer Risk-Predictive Molecular Biomarkers Specific to
Clinico-Epidemiological Contexts
10:00 AM - 10:30 AM EDT
Tuesday, March 23, 2021Room: V600 Zach Smith Speaker
Yujin Hoshida, MD, PhD
UT Southwestern Medical Center
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Liquid Biopsy in Hepatobiliary Cancers
10:30 AM - 11:00 AM EDT
Tuesday, March 23, 2021Room: V600 Zach Smith Speaker
Augusto Villanueva Rodriguez, MD, PhD
Icahn School of Medicine at Mount Sinai
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Mechanisms of Liver Carcinogenesis Define Specific Molecular and Phenotypic HCC Subgroups
11:00 AM - 11:30 AM EDT
Tuesday, March 23, 2021Room: V600 Zach Smith Speaker
Jessica Zucman-Rossi, MD, PhD
University Paris Descartes-HEGP
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Coffee Break
11:30 AM - 11:40 AM EDT
Tuesday, March 23, 2021Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications
11:40 AM - 12:10 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Jesper Bøje Andersen, PhD
University of Copenhagen
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches
12:10 PM - 12:40 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Robert Schwabe, MD
Columbia University
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Short Talk: Notch Inhibition Regresses Progenitor-Like HCCs by Inducing Hepatocyte Differentiation through Controlling C/EBPα Expression and HNF4α Activity
12:40 PM - 12:55 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Kerstin Seidel, PhD
Genentech
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
Short Talk: NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming into Intrahepatic Cholangiocarcinoma
12:55 PM - 1:10 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Sungjin Ko, PhD
University of Pittsburgh
Hepatobiliary Cancer Biomarkers and Molecular Subtypes
[Joint Session] Meet the Editors Roundtable
2:30 PM - 3:30 PM EDT
Tuesday, March 23, 2021Panelists
Elena Bellafante
Med- Cell Press
Francesco Giovinazzo
Frontiers
Xin (Cindy) Sun, PhD
Journal of Experimental Medicine (JEM)
Meet the Editors Roundtable
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
5:00 PM - 8:10 PM EDT
Tuesday, March 23, 2021Room: Multi Tech Session Co-Chairs
Lopa Mishra, MD
George Washington University
Alphonse Sirica, PhD
Virginia Commonwealth University
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Molecular Biomarkers in Hepatocellular Carcinoma
5:00 PM - 5:30 PM EDT
Tuesday, March 23, 2021Room: V300 Guy Coombes Speaker
Irene Oi Lin Ng, MD, PhD
University of Hong Kong
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers
5:30 PM - 6:00 PM EDT
Tuesday, March 23, 2021Room: V300 Guy Coombes Speaker
Xin Wei Wang, PhD
NCI, National Institutes of Health
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Implications of Genetic Heterogeneity in Hepatocellular Carcinoma (HCC)
6:00 PM - 6:30 PM EDT
Tuesday, March 23, 2021Room: V300 Guy Coombes Speaker
Renumathy Dhanasekaran, MD
Stanford University
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Coffee Break
6:30 PM - 6:40 PM EDT
Tuesday, March 23, 2021Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications
6:40 PM - 7:10 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Teh Bin Tean, MD, PhD
Duke-NUS Medical School
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Immune Therapies for HCC: is NASH-HCC Responding Different
7:10 PM - 7:40 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Josep Llovet, MD, PhD
Icahn School of Medicine at Mount Sinai
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal
7:40 PM - 7:55 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Bangyan Stiles, PhD
University of Southern California
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma
7:55 PM - 8:10 PM EDT
Tuesday, March 23, 2021Room: V100 Atticus Kiser Speaker
Chungui Xu
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers
Wednesday, March 24, 2021
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
10:00 AM - 1:05 PM EDT
Wednesday, March 24, 2021Room: Multi Tech Session Co-Chairs
Gregory Gores, MD
Mayo Clinic
Lopa Mishra, MD
George Washington University
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives
10:00 AM - 10:30 AM EDT
Wednesday, March 24, 2021Room: V300 Guy Coombes Speaker
Tim Greten, MD
NCI, National Institutes of Health
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma
10:30 AM - 11:00 AM EDT
Wednesday, March 24, 2021Room: V300 Guy Coombes Speaker
R. Kate Kelley, MD
University of California, San Francisco
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma
11:00 AM - 11:30 AM EDT
Wednesday, March 24, 2021Room: V300 Guy Coombes Speaker
Bruno Sangro, MD, PhD
Clinica Universidad de Navarra
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Coffee Break
11:30 AM - 11:40 AM EDT
Wednesday, March 24, 2021Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Short Talk: Identifying Effective Subtype-Specific Treatment Responses in Hepatocellular Carcinoma in Genetically Engineered Mouse Models
11:40 AM - 11:55 AM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Speaker
Miryam Müller, PhD
CRUK Beatson Institute
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Short Talk: A Cytosolic Complex Between the Nuclear Export Protein XPO7 and Sterile 20-like Kinase (SLK) Drives Cholangiocarcinoma, and Reveals a Translatable Therapeutic Target
11:55 AM - 12:10 PM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Speaker
Jonathan Hernandez, MD
NCI, National Institutes of Health
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Short Talk: Inhibition of YAP Activation Induces Cell Senescence and Autophagy while Blocking Cell Proliferation in Cholangiocarcinoma (CCA)
12:10 PM - 12:25 PM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Speaker
Massimiliano Cadamuro, PhD
University of Padua
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Short Talk: Tumor Methionine Metabolism Drives T-Cell Exhaustion in Hepatocellular Carcinoma
12:25 PM - 12:40 PM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Speaker
Man Hsin Hung, MD, PhD
NCI, National Institutes of Health
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Short Talk: Overcoming HCC Drug Resistance byTargeting Metabolic Flexibility Conferred by p53
12:40 PM - 12:55 PM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Speaker
Andreas Prokesch, PhD
Medical University Graz
Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
Closing Remarks (Organizers)
12:55 PM - 1:05 PM EDT
Wednesday, March 24, 2021Room: V100 Atticus Kiser Advances in Molecular and Immune Targeting of Hepatobiliary Cancers
